cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
A BioRegenEx MSC exosome vial on a laboratory bench beside documentation
BioRegenEx · Research

MSC Exosome Clinical Trials: What Registry Reviews Actually Show

← Back to Research Library
Reviewed by BioRegenEx Scientific Editorial Team
Published
Purpose Educational overview for physicians and researchers. Supplied for research use only.

Physicians and research clinics are asked about exosomes far more often than the clinical literature can answer. The most useful way to calibrate expectations is to look at what has actually been registered and reported in human studies of mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs). Three registry-based reviews published between 2023 and 2025 give a consistent picture: the field is active, early-stage, and still missing the standardized dosing and product data that later-phase development requires.

How Many MSC-EV Trials Are Registered?

The count depends on the search date, the registries searched, and the terms used, so the published figures differ slightly. A scoping review in Cytotherapy searched ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, and the Chinese Clinical Trial Registry in June 2022 and identified 73 trials of cell-derived EVs, of which 49 (67%) used MSC-derived EVs. A 2025 analysis in Frontiers in Medicine covering 2014 through early 2024 included 66 eligible MSC-EV trials. A separate 2025 review in Frontiers in Cell and Developmental Biology reported 64 registered MSC-EV trials on ClinicalTrials.gov as of January 2025.

Whichever number is used, the order of magnitude is the point. Dozens of MSC-EV studies are registered worldwide, compared with the more than one thousand registered trials of MSCs themselves. This is a young clinical field.

Which Conditions Are Being Studied?

Respiratory disease dominates. The Cytotherapy review found that COVID-19 and acute respiratory distress syndrome (ARDS) were the most common indications, and the later analyses confirm that the pandemic drove a sharp rise in registrations. Beyond the lung, the trials tabulated in the 2025 reviews span a wide range of research areas, including osteoarthritis and knee injury, myocardial infarction, amyotrophic lateral sclerosis, cirrhosis, inflammatory bowel disease, dystrophic epidermolysis bullosa, alopecia, diabetic foot ulcer, and retinitis pigmentosa.

Breadth should not be mistaken for depth. Most of these indications are represented by one or two small studies, and a registered trial is a plan to collect evidence, not evidence itself.

Trial Phase and Design: Mostly Early

The registry reviews agree that the large majority of MSC-EV studies are Phase 1 or Phase 1/2, built primarily to assess safety and feasibility. Controlled designs are not universal: in the Cytotherapy review, 25 of the 49 MSC-EV studies (51%) included a control group. Among the trials listed in the 2025 Frontiers in Cell and Developmental Biology review, a single Phase 3 study appears, a U.S. ARDS trial with a planned enrollment of 970 participants.

For clinicians, the practical reading is that efficacy conclusions remain preliminary for every indication. Early signals reported in ARDS, including a randomized Phase 2 study of a bone marrow MSC-derived EV product, are hypothesis-generating and await confirmation in larger trials.

Route and Dose: The Least Standardized Variables

The Frontiers in Medicine authors found intravenous infusion and aerosolized inhalation to be the predominant routes of administration, which reflects the weight of pulmonary indications. Their central observation concerns dose. They describe dose-response as a critical but underappreciated gap and suggest that effective doses may sit in a relatively narrow, route-dependent window. That suggestion rests on a small number of heterogeneous trials and should be treated as a hypothesis.

The underlying problem is that trials do not share a dose unit. Products are described variously by particle number, protein mass, volume, or the number of parent cells, which makes cross-trial comparison difficult. We cover the measurement issues in more detail in Understanding MSC Exosome Dosing: Particle Count vs. Protein Concentration.

Gaps the Reviewers Identify

The three reviews converge on the same list of unresolved issues. The Frontiers in Cell and Developmental Biology authors point to the lack of standardization in production processes, limited targeting after in vivo delivery, and scarce long-term biodistribution data. The Cytotherapy authors call for more standardized product characterization, quantifiable product quality attributes, and consistent outcome reporting so that studies can eventually be pooled.

These are manufacturing and documentation questions as much as clinical ones. Cell source, culture conditions, isolation method, and release testing all influence what is in the vial, which is why lot-level documentation matters for any research program. See How to Read a Certificate of Analysis (CoA) for MSC Exosomes for what to expect on that document.

What This Means for Research Clinics

The registry data support three measured conclusions. First, MSC-EVs are a legitimate and growing area of clinical investigation. Second, the human evidence is early-phase and concentrated in a few indications. Third, there are no FDA-approved exosome products for any indication; products in U.S. clinical investigation are studied under the investigational new drug pathway.

BioRegenEx supplies MSC-derived exosomes for research use only. Our material is cGMP-manufactured in an FDA-registered U.S. facility and ethically sourced from human umbilical cord (Wharton's Jelly) MSCs, with lot-specific documentation to support reproducible research. An overview of the science is available on our exosome research page.

References

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx exosome products are provided for research use only and are not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Any treatment decision is made solely between a patient and a licensed healthcare provider.

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.

Need 2026 pricing or a COA? Tell me where to send it — takes about 20 seconds.
Call 281-785-6877 Mon-Fri 8-5 CT
Licensed providers